[1] |
Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+CD25+CD4+ natural regulatory T cells in dominant self⁃tolerance and autoimmune disease[J]. Immunol Rev, 2006, 212: 8⁃27. DOI: 10.1111/j.0105⁃2896.2006.00427.x.
|
[2] |
Michalak⁃Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited[J]. Eur Cytokine Netw, 2011, 22(4): 160⁃168. DOI: 10.1684/ecn.2011.0294.
|
[3] |
Reich A, Welz⁃Kubiak K, Rams L. Apprehension of the disease by patients suffering from psoriasis[J]. Postepy Dermatol Alergol, 2014, 31(5): 289⁃293. DOI: 10.5114/pdia.2014.44010.
|
[4] |
Mesquita D, Cruvinel WM, Araujo JA, et al. Imbalanced of functional surface molecules in regulatory and effector T cells in systemic lupus erythematosus[J]. Braz J Med Biol Res, 2014, 47(8): 662⁃669. DOI: 10.1590/1414⁃431X20143483.
|
[5] |
Soler DC, Sugiyama H, Young AB, et al. Psoriasis patients exhibit impairment of the high potency CCR5(+) T regulatory cell subset[J]. Clin Immunol, 2013, 149(1): 111⁃118. DOI: 10.1016/j.clim.2013.06.007.
|
[6] |
Alunno A, Manetti M, Caterbi S, et al. Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications[J]. Mediators Inflamm, 2015, 2015: 751793. DOI: 10.1155/2015/751793.
|
[7] |
Mattozzi C, Salvi M, D′Epiro S, et al. Importance of regulatory T cells in the pathogenesis of psoriasis: review of the literature[J]. Dermatology, 2013, 227(2): 134⁃145. DOI: 10.1159/000353398.
|
[8] |
Fujimura T, Okuyama R, Ito Y, et al. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides[J]. Br J Dermatol, 2008, 158(6): 1256⁃1263. DOI: 10.1111/j.1365⁃2133.2008.08504.x.
|
[9] |
Yan KX, Fang X, Han L, et al. Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris[J]. Br J Dermatol, 2010, 163(1): 48⁃56. DOI: 10.1111/j.1365⁃2133.2010.09742.x.
|
[10] |
Chen L, Shen Z, Wang G, et al. Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris[J]. J Dermatol Sci, 2008, 51(3): 200⁃203. DOI: 10.1016/j.jdermsci.2008.04.015.
|
[11] |
Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation[J]. J Immunol, 2005, 174(1): 164⁃173. DOI:10.4049/jimmunol.174.1.164.
|
[12] |
Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases[J]. J Dermatol Sci, 2008, 50(1): 1⁃14. DOI: 10.1016/j.jdermsci.2007.05.016.
|
[13] |
Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model[J]. Nat Med, 2005, 11(1): 43⁃49. DOI: 10.1038/nm1162.
|
[14] |
Laurence A, Amarnath S, Mariotti J, et al. STAT3 transcription factor promotes instability of nTreg cells and limits generation of iTreg cells during acute murine graft⁃versus⁃host disease[J]. Immunity, 2012, 37(2): 209⁃222. DOI: 10.1016/j.immuni.2012.05.027.
|
[15] |
Bovenschen HJ, van de Kerkhof PC, van Erp PE, et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL⁃17A⁃producing cells and are found in lesional skin[J]. J Invest Dermatol, 2011, 131(9): 1853⁃1860. DOI: 10.1038/jid.2011.139.
|